Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies

BACKGROUND: The phase III PROSELICA (NCT01308580) and FIRSTANA (NCT01308567) trials investigated taxane chemotherapy among men with postdocetaxel metastatic, castration‐resistant prostate cancer (mCRPC) or chemotherapy‐naïve mCRPC, respectively. We present a post hoc analysis of patient‐reported hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiery‐Vuillemin, Antoine, Fizazi, Karim, Sartor, Oliver, Oudard, Stéphane, Bury, Denise, Ozatilgan, Ayse, Poole, Elizabeth M., Eisenberger, Mario, de Bono, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265338/
https://www.ncbi.nlm.nih.gov/pubmed/33904646
http://dx.doi.org/10.1002/onco.13803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265338/
https://www.ncbi.nlm.nih.gov/pubmed/33904646
http://dx.doi.org/10.1002/onco.13803

Ejemplares similares